Category: Press Releases

Posted on

Taconic Biosciences Adds New Humanized Immune System (HIS) Model to Its Portfolio For Immuno-Oncology Research

New huNOG-EXL EA Model Extends Study Windows Significantly

RENSSELAER, N.Y., Jan. 18, 2022 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of the huNOG-EXL EA (Early Access) humanized immune system (HIS) mouse. This product expands Taconic’s widely used HIS portfolio. huNOG-EXL EA significantly lengthens the study window during which a myeloid-lineage HIS mouse model can be used successfully.

Taconic’s huNOG-EXL models support human myeloid and lymphoid cells, making these mice especially useful for immuno-oncology research and other immune-related applications. With the longest lifespan of any myeloid-supportive HIS model, the original huNOG-EXL model (now called huNOG-EXL SA, or Standard Access) has been successfully applied in preclinical drug discovery research since 2016. The huNOG-EXL SA model is provided after a quality control step at 10 weeks post-engraftment. Feedback from users suggests research applications requiring particularly long study timelines or importation into regions with long quarantine periods present experimental and logistical hurdles that can limit the utility of the Standard Access (SA) model.

The new huNOG-EXL EA model removes those challenges by providing access to huNOG-EXL mice soon after engraftment, extending the useful study window. This makes the huNOG-EXL EA ideal for engraftment of slow-growing tumors, longer treatment paradigms, or various study customizations. Early access to an extended myeloid lineage model is also advantageous to researchers who face model importation quarantines, which would otherwise consume a significant portion of the useful study window for these mice. Because the huNOG-EXL EA model is shipped before an engraftment QC step is possible, it is made using cells from donors previously validated to engraft well so as to reduce the risk of engraftment failures.

“The huNOG-EXL EA model meets critical scientific needs for investigators performing immuno-oncology research or studying other immune-related diseases,” said Dr. Michael Seiler, vice president of commercial products at Taconic. “After conducting extensive research and development, along with rigorous beta testing with several industry partners, Taconic is excited to now offer the new model and expand the usefulness of this unique humanized mouse.”

To learn more about Taconic’s huNOG-EXL EA model, please contact us at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:

Nancy J Sandy

CEO

608-332-6320

Nancy.Sandy@taconic.com

Posted on

OKX overtakes global crypto exchanges as 2nd largest, rebrands as cross-platform services provider

Formerly OKEx, OKX’s new brand highlights the platform’s robust suite of crypto, NFT and DeFi investing products

VICTORIA, Seychelles, Jan. 18, 2022 (GLOBE NEWSWIRE) — OKX, which recently became the second largest cryptocurrency exchange in the world by spot trading volume, today announced a company-wide rebrand that reflects the dynamism and accelerating adoption of cryptocurrency. Founded in 2017 as a cryptocurrency trading service, OKX has since amassed over 20 million users and expanded its suite of digital asset investing products to include OKX Earn, a tool for earning passive crypto income; an NFT marketplace and decentralized application discovery hub; and most recently, MetaX, OKX’s new decentralized mode that features a cross-chain dashboard and self-custody Web 3.0 wallet for storing digital assets, including NFTs.

This shift, as highlighted by the company’s name change from OKEx to OKX, reflects the platform’s growing number of wealth creation opportunities beyond the exchange, which investors use to trade hundreds of digital assets on spot, margin and derivatives markets.

As part of the move, OKX has declared its mission to be “to remove barriers to wealth creation by giving you access to everything our decentralized future holds.” This underscores the platform’s ongoing evolution towards decentralization, which includes giving investors the option to self-custody their digital assets. Distinct from other centralized cryptocurrency exchanges, OKX is committed to gradually decreasing the company’s level of involvement in user activity, with the ultimate goal of shedding intermediation entirely.

“OKX is moving beyond the standard centralized exchange model to give our customers an end-to-end cryptocurrency experience,” said Jay Hao, CEO of OKX. “Most importantly, we’re doing this while upholding the core principles of crypto — decentralization and autonomy. Our goal is to give customers the tools they need to easily and securely earn, transfer, and spend their wealth as they see fit, without intermediation from us. We’ve dropped the ‘E’ from our name because we’re so much more than an exchange, just like crypto is so much more than a speculative asset.”

OKX, which lists over 250 digital assets and has long held the #1 rank for cryptocurrency futures trading volumes, recently became the second largest cryptocurrency spot trading platform in the world. In 2021, total trading volume on the platform, including spot and derivatives instruments, grew over 700%, while the number of trades executed on the platform increased over 480%. Staking, savings and DeFi offerings via OKX Earn saw over $5.1 billion deposited by users, and paid out over $314 million in passive income this past year.

To learn more, please visit OKX.com and follow @OKX on Twitter.

About OKX

Founded in 2017, OKX is a world leading cryptocurrency exchange and ecosystem. OKX has innovatively adopted blockchain technology to reshape the financial ecosystem and offers some of the most diverse and sophisticated products, solutions and trading tools on the market. Trusted by more than 20 million people in 180 regions across the globe, OKX’s mission is to remove barriers to wealth creation by offering access to everything the decentralized future holds. With its unwavering commitment to innovation, OKX envisions a world of financial inclusion for all through the power of crypto and decentralized finance.

Contact us

Email: media@okx.com
Olivia Capozzalo:
olivia.capozzalo@okx.com
@oliviacap (Telegram)

Posted on

Good news for kung fu enthusiasts around the world – Shaolin Temple launches kung fu online games

DENGFENG, China, Jan. 18, 2022 /PRNewswire/ — With the Chinese New Year around the corner, China’s Songshan Shaolin Temple and Shaolin Culture Centers across the world have launched a global kung fu contest – “Happy Chinese New Year: Shaolin Kung Fu Online Games.”

“Shaolin kung fu boasts the value of fitness, enlightenment, and harmony,” said the abbot of the Shaolin Temple, Master Shi Yongxin. “As countries around the world battle the COVID-19 pandemic, the Shaolin Temple launched the competition online with the aspiration of promoting peace, friendship, and health, hoping that kung fu fans around the globe gain health, fitness, and happiness,” the abbot added.

The Shaolin Temple organizes year-end kung fu examinations for the monks at the end of each year to encourage kung fu monks to be more brave and diligent.

This year, the examination will be launched online for kung fu lovers of all ages across the globe. Participants will only need to upload a video to the official website of the activity.

The online kung fu games promote communication and interaction between people around the globe against the backdrop of epidemic curbing. The online games are not only an arena for global competitors but also a joyous “family reunion” of all kung fu enthusiasts.

The Chinese zodiac sign of 2022 is the Tiger, and the tiger represents justice, majesty, bravery, and diligence in Chinese culture, which identifies with the concept of Shaolin kung fu.

Shaolin Kung fu has a long history of more than 1,500 years and is one of China’s top-level martial art schools with a complete system. As a national intangible cultural heritage of China, Shaolin kung fu illustrates the desire for supernatural powers and the pursuit of extraordinary wisdom.

The Shaolin Temple has established Shaolin Culture Centers in more than 120 cities on five continents, with more than tens of millions of disciples. Former South African President Nelson Mandela praised Shaolin culture for the human values it instills. Moreover, Stephen Orlins, president of the National Committee on United States-China Relations recalled the legacy of the “ping-pong diplomacy” when talking about Shaolin kung fu, after watching a kung fu performance at the United Nations headquarters.

Registration for the games is now open until January 20 at 24:00, local time. Please visit the official website and App of the Shaolin Temple for more details.

Photo – https://mma.prnewswire.com/media/1728275/image_1.jpg

Posted on

Après avoir lancé la première série de téléviseurs laser trichromes L9 au monde, Hisense introduit maintenant la série 100L9G en Afrique

Le CAP, Afrique du Sud, 17 janvier 2022  /PRNewswire/ — Hisense, fournisseur de téléviseurs et d’appareils électroménagers de haute performance, a annoncé que le premier téléviseur L9G TriChroma Laser de 100 pouces au monde, doté d’une résolution 4K UHD, d’une gamme de couleurs BT 2020 de 107 % et du système de haut-parleurs Dolby Atmos®, est désormais disponible en Afrique.

Après l’introduction du premier téléviseur laser 4K Dual Colour au monde en Afrique, l’ajout du 100L9G au portefeuille de produits en expansion d’Hisense en Afrique démontre l’engagement continu de la société envers les consommateurs de la région en introduisant des technologies plus sophistiquées et des produits de haute qualité sur le continent.

« Au cours de l’année dernière, l’unité de vente de téléviseurs laser de Hisense South Africa Company a connu une augmentation de 194 %, ce qui a renforcé notre confiance pour aller de l’avant et présenter nos produits haut de gamme aux clients locaux. Grâce aux technologies d’amélioration de l’image et de triple laser de pointe de Hisense, le 100L9G offrira une expérience cinématographique à domicile à nos clients dans la région », a déclaré Patrick Hu, directeur du marketing de Hisense South Africa.

Alimenté par le moteur laser TriChroma d’Hisense qui utilise trois lasers de couleurs primaires pures pour porter la pureté des couleurs à un autre niveau, le 100L9G établit une nouvelle référence pour l’expérience de visionnage à domicile avec sa gamme de couleurs BT 2020 à 107 %, atteignant jusqu’à 151 % de la norme de couleur du film DCI-P3 et battant la plupart des téléviseurs LED haut de gamme sur le marché. Ses performances colorimétriques inégalées sont associées à une qualité d’image 4K HDR 10, ainsi qu’à deux haut-parleurs Dolby Atmos® de 20W qui offrent un réalisme suprême et un paysage sonore riche, offrant une expérience audiovisuelle totalement immersive qui transporte le spectateur dans la scène.

Le 100L9G est livré avec un écran ALR Daylight de 100 pouces bord à bord, qui présente des capacités de rejet de la lumière ambiante et tire parti de la luminosité de 3 000 Lumens du projecteur pour apporter une vivacité supplémentaire aux images dans les environnements à lumière naturelle. Doté d’un corps noir élégant, il présente un design compact et minimaliste qui s’harmonise et se fond dans l’installation de divertissement à domicile et l’espace de vie de l’utilisateur.

Conçu dans un souci de protection des yeux, le 100L9G est équipé d’une solution certifiée TUV Rheinland pour minimiser la fatigue oculaire, ainsi que de la fonction de luminosité automatique qui adapte automatiquement la luminosité de l’écran aux conditions d’éclairage de la pièce.

Le 100L9G est alimenté par le système d’exploitation VIDAA OS d’Hisense qui permet d’accéder à plus de 5 000 applications et jeux sur le grand écran et à un grand nombre de films et de spectacles. Il promet également plus de 25 000 heures de divertissement qui se traduisent par plus de 10 000 films.

Photo – https://mma.prnewswire.com/media/1726851/100L9G_KV.jpg

Posted on

Seegene’s Allplex™ SARS CoV-2 FluA/FluB/RSV Assay approved under Health Canada’s Interim Order

Seegene’s syndromic assay detects COVID-19 and Influenza A/B/RSV infections in a single test.

SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ — Seegene Inc. (KQ 096530), South Korea’s leading molecular diagnostic company, announced it has received approval of its Allplex™ SARS CoV-2 FluA/FluB/RSV Assay under Health Canada’s Interim Order on January 11.

Logo

Seegene’s Allplex™ SARS CoV-2 FluA/FluB/RSV Assay is a multiplex real-time PCR assay that enables simultaneous amplification and differentiation of respiratory symptoms. In a single test, it can distinguish among Influenza A, B, RSV, and COVID-19. This assay expected to play a crucial role in responding against the potential ‘twindemic’ as the country is forecasting a surge in both flu patients and COVID-19 patients.

To support Canada experiencing surging demand for COVID-19 tests, Seegene delivered 340,000 COVID-19 tests to Canada by a charter flight on January 13.

“Demand for COVID-19 tests is skyrocketing due to the resurgence of confirmed cases,” said Ho Yi, Chief Sales and Marketing Officer of Seegene. “We are fully prepared to supply enough test kits globally and will continue to be strong global partners in the effort to manage the spread of COVID-19.” This latest approval is expected to be a significant opportunity for the company, as it will allow Seegene to raise its product awareness in surrounding countries of Canada such as Latin America and others.

Visit www.seegene.com for more information.

About Seegene, Inc.

Seegene, Inc. was founded in Seoul, South Korea in 2000 and has subsidiaries in the U.S.A., Canada, Germany, Italy, Mexico, Brazil, Colombia, and the Middle East. Seegene, Inc. is an in-vitro diagnostics (IVD) company that has been turning innovative technologies into products through its pioneering R&D activities. Seegene owns its original patent technology including DPO™ (Dual Priming Oligonucleotide) for multiple target amplification; TOCE™ for multiple target detection in a single channel; MuDT™, the world’s first real-time PCR technology that provides individual Ct values for multiple targets in a single channel for quantitative assays.; and mTOCE™ multiplex mutation detection technology. With these cutting-edge molecular diagnostic (MDx) technologies applied to diagnostic kits and other tools, Seegene has enhanced the sensitivity, specificity, and disease-coverage per a test of PCR (polymerase chain reaction) to unprecedented levels by providing accurate high-multiplex PCR products that target and detect genes of multiple pathogens simultaneously per each fluorescence channel. This feature dramatically saves testing time and cost. Seegene continues to set new standards in MDx through cutting-edge innovations.

Logo – https://mma.prnewswire.com/media/1357790/Seegene_logo_Logo.jpg

Posted on

Le U.S. Institute of Peace ouvre les candidatures pour l’édition 2022 du Women Building Peace Award

Ce prix annuel récompense les femmes issues de pays touchés par des conflits et qui luttent pour la paix.

WASHINGTON, 14 janvier 2022 /PRNewswire/ — Le U.S. Institute of Peace (USIP) annonce l’ouverture des candidatures pour l’édition 2022 du Women Building Peace Award. Ce prix annuel prestigieux rend hommage aux femmes qui amènent la paix dans les pays touchés par des conflits violents.

La période de mises en candidature prendra fin le 14 février 2022. La lauréate sera reconnue lors d’une cérémonie organisée par l’USIP en octobre 2022.

D’innombrables femmes risquent leur vie pour instaurer la paix dans leurs communautés, dirigeant des mouvements pour la justice et l’inclusion, bien que leurs efforts soient souvent ignorés. L’USIP est déterminé à en faire davantage pour soutenir et célébrer ces femmes et leur impact en tant qu’agentes de paix. L’institut invite les organisations et les personnes du monde entier à reconnaître les femmes exceptionnelles qui ont consacré leur vie à la paix et à leur rendre hommage.

L’USIP encourage fortement les mises en candidature de femmes qui n’ont jamais été reconnues pour leur action de consolidation de la paix. Les candidatures seront examinées en fonction des critères suivants :

  • Engagement pour la paix : une femme montrant un engagement en faveur de la paix par ses actions pour la prévention ou la résolution de conflits de façon non violente dans un pays ou une région fragile ou touché par des conflits.
  • Leadership exceptionnel : une femme qui incarne un leadership exceptionnel par sa vision et le caractère novateur de son approche, et qui a gagné le respect des autres de par les efforts qu’elle déploie en faveur de la paix.
  • Praticien exceptionnel : une femme, intervenante en consolidation de la paix, qui travaille avec les membres des communautés locales, nationales ou internationales de manière inclusive et participative.
  • Incidence importante : une femme dont l’action en faveur de la paix a donné des résultats tangibles.

La lauréate de l’édition 2022 sera désignée par le Women Building Peace Council, un groupe d’éminents experts qui conseillent l’USIP sur les questions de genre et de consolidation de la paix.

Josephine Ekiru , du Kenya, et Rita Lopidia, du Sud-Soudan, sont des lauréates des éditions précédentes du Women Building Peace Award. L’USIP a désigné 19 finalistes du prix depuis sa création en 2019.

Pour en savoir plus sur le prix et pour proposer la candidature d’une artisante de la paix, veuillez consulter le site www.usip.org/womenbuildingpeace.

Pour en savoir plus sur l’USIP, veuillez consulter le site Web suivant : https://www.usip.org/about.

Logo : https://mma.prnewswire.com/media/1274028/United_States_Institute_of_Peace_Logo.jpg

Posted on

After Launching World’s First TriChroma Laser TV L9 Series, Hisense Now Brings the Series’ 100L9G to Africa

CAPE TOWN, South Africa, Jan. 14, 2022 /PRNewswire/ — Hisense, provider of high-performance televisions and appliances, has announced the world’s first 100-inch L9G TriChroma Laser TV featuring 4K UHD resolution, 107% BT 2020 Colour Gamut, and Dolby Atmos® speaker system, is now available in Africa.

Following the introduction of the world’s first Dual Colour 4K Laser TV to Africa, the addition of the 100L9G to Hisense’s expanding product portfolio in Africa demonstrates the company’s continuous commitment to the region’s consumers by introducing more sophisticated technologies and high-quality products to the continent.

“Over the past year, the laser TV sales unit of Hisense South Africa Company have seen a 194% increase, which has boosted our confidence to push ahead to present our premium products to local customers. Back by Hisense’s industry-leading image-enhancing and triple laser technologies, 100L9G will deliver a home cinematic experience to our customers in the region,” said Patrick Hu, marketing director of Hisense South Africa.

Powered by Hisense’s TriChroma Laser Engine that uses three pure primary colour lasers to take colour purity to another level, 100L9G sets a new benchmark for home viewing experience with its 107% BT 2020 Colour Gamut, reaching up to 151% of the DCI-P3 film colour standard and beating most high-end LED TVs on the market. Its unparalleled colour performance is paired with 4K HDR 10 picture quality, as well as two 20W Dolby Atmos® speakers that deliver supreme realism and rich soundscape, offering a fully immersive audio-visual experience that transports the viewer into the scene.

The 100L9G comes with a 100-inch edge-to-edge ALR Daylight Screen that features ambient light rejection capabilities and takes advantage of the projector’s 3000 Lumens brightness to bring extra vividness to images in environments with natural light. Sporting a sleek, black body, it comes in a compact and minimalist design that harmoniously matches and blends into the user’s home entertainment setup and living space.

Designed with eye protection in mind, 100L9G is equipped with a TUV Rheinland-certified solution to minimalize eyestrain, along with the auto-brightness feature that automatically adapts the screen brightness to the lighting condition of the room.

The 100L9G is powered by Hisense’s VIDAA OS that brings more than 5,000 apps and games to the big screen and provides access to a large number of movies and shows. It also promises 25,000+ entertainment hours that translate to over 10,000 films.

Posted on

Sungrow and KarmSolar Cooperate on the Microgrid BESS Project for Cairo 3A Group

CAIRO, Jan. 14, 2022 /PRNewswire/ — Recently, Sungrow, the global leading inverter solution supplier for renewables, signed a new BESS contract with KarmSolar, Egyptian largest private sector solar energy provider. Sungrow will provide 2.576MWp PV inverter and 1MW/3.957 MWh energy storage system to build a microgrid for Cairo 3A Poultry Company. This microgrid, by its commission in May, 2022, will generate the energy resources needed by this large-scale company from solar power rather than relying on diesel generator and burning fossil fuels.

Sungrow and KarmSolar build the microgrid for Cairo3A Poultry Company

North Africa boasts enormous potential of solar power uptake with year-round sunshine. Egypt also set the goal of achieving 42% of its electricity from renewable sources by 2035. However, large-scale utility projects are not that easy to secure because of the pressure to get huge investment and public support. Hence, market trend follows smaller projects with more tangible results, such as microgrid and off-grid Solar plus ESS projects.

Sungrow will help build such a microgrid BESS project in Bahariya Oasis. Sungrow offers the 1500V solar plus storage solution: ST3956KWH(L)-1375UD. As all devices are integrated, the system has less units and occupies less land, and in this way, it is more economical and simpler to transport, install and operate. Equipped with EMS, the post maintenance procedure is also streamlined and smart. In addition, being compatible to bifacial solar modules, and adopting higher-power PCS (max. efficiency up to 99%), this system achieves higher yield. As Bahariya Oasis is a depression with agriculture as the main sector, using clean power bears long-term significance for environmental protection and sustainable development.

Logo

Alvin Shi, Managing Director of MENA Region, Sungrow said, “The Cairo 3A BESS project is the second one Sungrow achieved in Egypt. We are also supplying the largest solar-plus-storage plant locating Sukari gold mine. For years, Sungrow endeavors to meet the safety and reliability needs of our customers by pioneering zero-carbon microgrids. The Cairo 3A project demonstrates how microgrid could significantly benefit sustainable agricultural development and local people.”

Now Sungrow has achieved a considerably large amount of installation capacity in Egypt. As Egyptian renewable energy market grows steadily and the energy storage sector is emerging stronger, Sungrow will be committed to providing high-quality solutions and tailored services to help Egypt achieve a realistic and cost-effective energy transition.

About KarmSolar

KarmSolar, with Électricité de France (EDF) being its strategic shareholder, spearheads the growth of the private solar energy market in Egypt, revolutionizing the solar market through innovative and integrated solutions across the residential, industrial, agricultural, commercial and touristic sectors. With unique technical and financial expertise, supported by tits in-house Research and Development, KarmSolar leads the Egyptian market with the largest portfolio of private solar energy projects.

About Sungrow

Sungrow Power Supply Co., Ltd. (“Sungrow”) is the world’s most bankable inverter brand with over 182 GW installed worldwide as of June 2021. Founded in 1997 by University Professor Cao Renxian, Sungrow is a leader in the research and development of solar inverters with the largest dedicated R&D team in the industry and a broad product portfolio offering PV inverter solutions and energy storage systems for utility-scale, commercial & industrial, and residential applications, as well as internationally recognized floating PV plant solutions. With a strong 24-year track record in the PV space, Sungrow products power installations in over 150 countries. Learn more about Sungrow by visiting: www.sungrowpower.com.

Photo – https://mma.prnewswire.com/media/1726681/image.jpg
Logo – https://mma.prnewswire.com/media/1344575/Logo.jpg

Posted on

AscendEX Lists the Marvelous NFT Token, MNFT

International, Jan. 13, 2022 (GLOBE NEWSWIRE) — AscendEX is excited to announce the listing of the Marvelous NFT Token (MNFT) under the trading pair MNFT/USDT on AscendEX starting on January 14 at 5:30 p.m. UTC.

Marvelous NFTs is a blockchain game development company and the official intellectual property licensee of Bad Days, a decentralized strategy game and blockchain-powered site. Running on the Ethereum network and utilizing the Polygon Layer 2 protocol, Bad Days implements ERC-721 and ERC-1155 custom-developed smart contracts to enable users to own, collect, breed, sire, battle, and play unique limited-edition digital assets and crypto collectibles.

Bad Days players can develop and customize their assets, creating an immersive and multi-dimensional user experience where players can personalize and tailor their strategies to compete against other players in a series of battle scenarios.

The core token of the Bad Days ecosystem is the Marvelous NFT token, MNFT. Operating as the core currency in gameplay, MNFT allows players to not only make in-game purchases but also stake their assets to earn increased yield. MNFT tokens additionally feature two deflationary mechanisms, including fee distribution and buy-back mechanism, to maintain the stability of the token and broader game economy.

Players of Bad Days are also able to interact with the Fuse Token, yet another operational token within the Bad Days battle environments. The Fuse Token, similar to MNFT, aims at producing player-generated wealth throughout the game ecosystem. Ultimately, players are rewarded for continuous engagement and top-tier game strategy within the Bad Days platform.

Through the development of Bad Days, the Marvelous NFTs team has continued its mission to drive mainstream adoption of blockchain and GameFi by delivering high-quality blockchain-based gaming, unique opportunities for NFT ownership, and easy-to-comprehend play-to-earn mechanisms.

With the listing of MNFT, AscendEX strives to continue demystifying the world of blockchain-based gaming, allowing for more individuals to participate in the blockchain ecosystem.

About AscendEX
AscendEX is a global cryptocurrency financial platform servicing more than one million institutional and retail traders with the resources needed to obtain more value from their crypto investments. Operating at the nexus of centralized finance and decentralized finance, AscendEX’s platform features access to margin, futures, and spot trading, a robust wallet infrastructure, and staking support for over 200 industry-leading blockchain projects, all producing industry-leading yields and returns, further driving the growth of the crypto ecosystem. In efforts to cultivate scalable and secure forms of decentralized financing, AscendEX has emerged as a leading platform by ROI on its “initial exchange offerings” through supporting some of the industry’s most innovative projects from the DeFi ecosystem.

To learn more about how AscendEX leverages best practices from both Wall Street and the cryptocurrency ecosystem to extract the highest value per dollar to its users, please visit:

Website: https://ascendex.com
Twitter: https://twitter.com/AscendEX_Global
Telegram: https://t.me/AscendEXEnglish
Medium: https://medium.com/ascendex

About Marvelous NFTs
Marvelous NFTs is a blockchain game development company and the official intellectual property licensee of Bad Days, a decentralized application that runs on the Ethereum network utilizing the Polygon layer two protocol to avoid high gas fees. Bad Days was designed to be a fun and interactive game that gives users the ability to own, buy, sell, collect, upgrade, battle, and play unique limited edition digital assets from the Bad Days universe in an exciting player vs. player strategy game.

For more information and updates, please visit:

Website: https://marvelousnfts.com/
Twitter: https://twitter.com/MarvelousNfts_
Telegram: https://t.me/baddayscom

Attachment

Marketing Department
AscendEX
marketing@ascendex.com
Posted on

AscendEX Lists Battle of Guardians Token, BGS

International, Jan. 13, 2022 (GLOBE NEWSWIRE) — AscendEX is thrilled to announce the listing of the Battle of Guardians Share Token (BGS) under the trading pair BGS/USDT starting on January 14th at 2 p.m. UTC.

Battle of Guardians (BOG) is a real-time, multiplayer NFT fighting game that allows players to utilize their NFT assets as fighting avatars in an all-out battle of skills, where heightened skill is recognized with in-game rewards. Developed in Unreal Engine and built atop the Solana Network, BOG was designed with multiplayer capabilities that allow global players to engage in fierce, multi-realm battles in the expansive Sci-Fi game ecosystem. The project currently offers a selection of 30 unique NFTs and is equipped with an NFT Synthesis feature that allows players to upgrade the tier of their fighting avatars. BOG is being developed for PC-based gaming, with iOS and Android cross-platform multiplayer features becoming available in the future.

Recently, the play-to-earn model has become the standard for new-to-market, blockchain-based gaming ecosystems. The convergence of gaming and finance through NFTs has become an exciting and interactive way for players of games, and owners of NFTs, to earn real-world rewards. BOG aims to emphasize the “play” aspect of the play-to-earn movement by offering multiple modes of play. In BOG gameplay, players can battle in Player vs. Environment (PvE), Player vs. Player (PvP), or Tournament modes, using their collection of NFT avatars. With a tiered system of playable NFTs, a variety of gaming modes, and a rewards model in place, BOG will become the go-to platform for players to test their skills and agility while earning rewards in-game.

A unique feature of BOG’s NFT structure is the ability for players to rent NFTs, which adds yet another revenue stream for players looking to leverage the BOG ecosystem. Owners of specific NFTs can rent their assets out to players who are eager to play the game, but do not yet want to commit to purchasing their own asset. By implementing this mechanism, both established players and inquisitive newcomers can earn increased in-game rewards, maximizing the utility of the NFTs featured in the BOG game.

To further incentivize players for continued gameplay and reward players for remarkable in-game achievements, Battle of Guardians will feature two tokens: the Battle of Guardians Share token (BGS) and the Fighting Points token (FP). Both tokens will be utilized within the game’s various modes for purchasing NFT characters and in-game assets, whereas BGS can uniquely be leveraged as a governance token to contribute to the development of the game. Players will also have the ability to stake their BGS tokens to generate additional yield and further their involvement in the BOG ecosystem.

AscendEX is excited to debut the trading of the BGS token and support the growth of the play-to-earn GameFi Ecosystem.

About AscendEX
AscendEX is a global cryptocurrency financial platform servicing more than one million institutional and retail traders with the resources needed to obtain more value from their crypto investments. Operating at the nexus of centralized finance and decentralized finance, AscendEX’s platform features access to margin, futures, and spot trading, a robust wallet infrastructure, and staking support for over 200 industry-leading blockchain projects, all producing industry-leading yields and returns, further driving the growth of the crypto ecosystem. In efforts to cultivate scalable and secure forms of decentralized financing, AscendEX has emerged as a leading platform by ROI on its “initial exchange offerings” through supporting some of the industry’s most innovative projects from the DeFi ecosystem.

To learn more about how AscendEX leverages best practices from both Wall Street and the cryptocurrency ecosystem to extract the highest value per dollar to its users, please visit:

Website: https://ascendex.com
Twitter: https://twitter.com/AscendEX_Global
Telegram: https://t.me/AscendEXEnglish
Medium: https://medium.com/ascendex

About Battle of Guardians
Battle of Guardians is a real-time multiplayer NFT Fighting Game that allows players to utilize their NFT asset as Fighters in the battlefield. Battle of Guardians is multiplayer ready, built by a game studio with 7+ years of experience.

For more information and updates, please visit:

Website: https://battleofguardians.com/
Twitter: https://twitter.com/BOG_Official_
Telegram: https://t.me/battleofguardianschat

Attachment

Marketing Dept
AscendEX
marketing@ascendex.com
Posted on

U.S. Institute of Peace Nominations Are Open for the 2022 Women Building Peace Award

Annual award recognizes women peacebuilders from conflict-affected countries.

WASHINGTON, Jan. 13, 2022 /PRNewswire/ — The U.S. Institute of Peace (USIP) announces nominations are open for the 2022 Women Building Peace Award. This prestigious annual award honors women who are building peace in countries impacted by violent conflict.

The nominations period will run until February 14, 2022. The awardee will be recognized at a ceremony organized by USIP in October 2022.

Countless women risk their lives to create peace in their communities, leading movements for justice and inclusivity despite often being overlooked in their efforts. USIP is committed to doing more to support and celebrate these women and the impact they have as agents of peace. USIP invites organizations and people across the globe to take part in identifying and honoring exceptional women who have dedicated their lives to peace.

USIP strongly encourages nominations for women who have not been previously recognized for their peacebuilding work. Nominations will be reviewed based on the following criteria:

  • Commitment to Peace: A woman who shows a commitment to peace through her work to prevent or resolve conflict nonviolently in a fragile or conflict-affected country or region.
  • Exceptional Leadership: A woman who embodies exceptional leadership through her vision and innovation and has earned the respect of others in the pursuit of peace.
  • Outstanding Practitioner: A woman who is a peacebuilding practitioner and works with members of local, national or international communities in an inclusive and participatory manner.
  • Substantial Impact: A woman whose peacebuilding work has led to tangible results.

The 2022 award winner will be chosen by the Women Building Peace Council, a group of distinguished experts who advise USIP on matters of gender and peacebuilding.

Previous recipients of the Women Building Peace Award include Josephine Ekiru of Kenya and Rita Lopidia of South Sudan. Nineteen women have been recognized by USIP as finalists for the award since its inception in 2019.

For information on the award and to nominate a woman peacebuilder, visit: www.usip.org/womenbuildingpeace.

For information on USIP, visit: https://www.usip.org/about.

Logo – https://mma.prnewswire.com/media/1274028/United_States_Institute_of_Peace_Logo.jpg

Posted on

Adagio Therapeutics Divulga Resumo da Atividade Neutralizante do ADG20 Contra Variantes do SARS-CoV-2 e Descreve Iniciativas para Abordar o Omicron

Publicações recentes de vários laboratórios independentes mostram que o ADG20 tem atividade neutralizante com potência comparável a outros anticorpos que retêm atividade contra o Omicron

Múltiplos Esforços em Andamento para Abordar Variantes Omicron e Potenciais Futuras de SARS-CoV-2

WALTHAM, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) — A Adagio Therapeutics, Inc., (Nasdaq: ADGI), uma empresa biofarmacêutica de estágio clínico focada na descoberta, desenvolvimento e comercialização de soluções com base em anticorpos para doenças infecciosas com potencial pandêmico, divulgou hoje um resumo das descobertas recentes relatadas em três publicações separadas que mostram que o ADG20, seu anticorpo monoclonal principal (mAb), tem atividade de neutralização contra a variante Omicron (B.1.1.529) do SARS-CoV-2 e delineou iniciativas para abordar as variantes preocupantes atuais e futuras do SARS-CoV-2. A Adagio está avaliando o ADG20 em estudos clínicos globais de Fase 2/3 para a prevenção e tratamento da COVID-19. A Adagio está colaborando com a Food and Drug Administration (FDA) dos EUA em relação a possíveis atualizações de protocolo dos seus ensaios clínicos globais de Fase 2/3, incluindo uma dose aumentada do ADG20 para a potencial prevenção e tratamento da COVID-19 resultante da variante Omicron.

Atividade Neutralizante do ADG2 Contra Omicron
Estudos in vitro recentemente publicados examinaram as potências de neutralização de grandes painéis de mAbs contra a variante Omicron em ensaios autênticos e de pseudovírus. Os resultados em todos os três estudos mostram que entre os mAbs em desenvolvimento clínico em estágio final ou com Autorização de Uso de Emergência (EUA), o ADG20 é um dos poucos mAbs que demonstraram atividade neutralizante contra o Omicron. Em dois ensaios de neutralização autênticos distintos contra Omicron, os dados mostram que o ADG20 tinha um IC50, uma medição da potência de neutralização, de aproximadamente 0,4 a 1,1 µg/mL, que é comparável com os outros dois mAbs ativos, sotrovimabe e AZD7742.

“O que é essencial para a avaliação da potencial eficácia clínica dos mAbs de SARS-CoV-2 é a potência de neutralização pelo mAb contra uma variante específica. Embora as descobertas possam mostrar que o ADG20 reduziu a potência contra o Omicron quando comparado à sua alta potência contra todas as outras variantes preocupantes, incluindo a Delta, os dados indicam que o ADG20 está entre os poucos mAbs que demonstram atividade neutralizante contra a variante Omicron, justificando, com isso, a continuação do seu desenvolvimento”, disse Laura Walker, Ph.D., diretora científica e cofundadora da Adagio.

Esses dados se somam aos dados in vitro divulgados anteriormente de vários estudos pré-clínicos que mostraram que o ADG20 retém a atividade contra outras variantes preocupantes, incluindo Alfa, Beta, Delta e Gama, e que o ADG20 retém a atividade neutralizante contra um painel diversificado de variantes circulantes de SARS-CoV-2, incluindo as variantes Lambda, Mu e Delta plus.

Atualização do Ensaio Clínico para Abordar o Omicron
A Adagio continua a avaliar o ADG20 nos seus ensaios clínicos de EVADE e STAMP. A Adagio está colaborando com a FDA na estratégia de dosagem, incluindo uma dose aumentada de ADG20, e outras atualizações de protocolo à luz da disseminação da variante Omicron. A Adagio deu uma pausa na inscrição de novos pacientes na dose de 300 mg em ambos os ensaios clínicos, enquanto a empresa atualiza seus protocolos. O acompanhamento e o monitoramento de pacientes que receberam anteriormente o ADG20 continuam de acordo com os protocolos originais.

Esforços Adicionais para Abordar as Variantes Omicron e futuras
Além das atualizações dos seus ensaios clínicos, a Adagio está buscando várias estratégias para abordar as variantes Omicron e futuras que potencialmente possam surgir. Aproveitando sua parceria exclusiva com a Adimab LLC, líder global em engenharia de anticorpos, a Adagio está explorando o potencial de projetar o ADG20 para aprimorar ainda mais a ligação à variante Omicron para aumentar sua potência de neutralização contra a Omicron, mantendo sua ampla neutralização contra outras variantes preocupantes do SARS-CoV-2. Paralelamente, Adagio está avaliando centenas de mAbs da sua biblioteca proprietária de anticorpos SARS-CoV-2 anteriormente isolados quanto à sua potência de neutralização contra Omicron. Tal mAb neutralizante adicional pode ser desenvolvido como um produto autônomo ou como parte de uma abordagem conjunta. Esses esforços estão em andamento, e a empresa prevê a conclusão preliminar da sua pesquisa no primeiro trimestre de 2022.

“O SARS-CoV-2 é um vírus em rápida evolução e a Adagio está empenhada em se adaptar com a mesma rapidez. Está abundantemente claro que nenhum produto único irá abordar totalmente a natureza em evolução da pandemia da COVID-19, e que são necessárias várias soluções preventivas e terapêuticas. Com base nos dados internos e descobertas de terceiros, estamos confiantes de que o ADG20 pode ser uma ferramenta importante na luta contra esse vírus”, acrescentou Tillman Gerngross, Ph.D., cofundador e diretor executivo da Adagio.

Sobre o ADG20
O ADG20, um anticorpo monoclonal em investigação direcionado à proteína Spike do SARS-CoV-2 e coronavírus relacionados, está sendo avaliada em testes clínicos em todo o mundo quanto à prevenção e ao tratamento da COVID-19, a doença causada pelo SARS-CoV-2. O ADG20 foi criado para ter uma atividade de neutralização ampla de alta potência contra SARS-CoV-2 e sarbecovírus de clado 1 adicionais, concentrando-se em um epítopo altamente conservado no domínio de ligação ao receptor. O ADG20 foi projetado para fornecer uma meia-vida prolongada de proteção durável. Dados in vitro de vários estudos pré-clínicos indicam que o ADG20 mantém atividade neutralizante contra todas as variantes preocupantes conhecidas do SARS-CoV-2. Em um teste de Fase 1, o ADG20 foi bem tolerado sem sinais de problemas de segurança identificados em um acompanhamento mínimo de três meses em todas as coortes. O ADG20 não foi aprovado para uso em nenhum país e a sua segurança e eficácia ainda não foram estabelecidas.

Sobre a Adagio Therapeutics
A Adagio (Nasdaq: ADGI) é uma empresa biofarmacêutica de estágio clínico focada na descoberta, desenvolvimento e comercialização de soluções com base em anticorpos para o tratamento de doenças infecciosas com potencial pandêmico, inclusive COVID-19 e gripe. O portfólio de anticorpos da empresa foi otimizado com os recursos de engenharia de anticorpos líderes da indústria da Adimab, e foi criado para fornecer aos pacientes e médicos o potencial para uma combinação de potência, amplitude, proteção durável (via extensão de meia-vida), capacidade de fabricação e acessibilidade. O portfólio de anticorpos contra SARS-CoV-2 da Adagio inclui múltiplos anticorpos amplamente neutralizantes não competitivos com epítopos de ligação distintos, liderados por ADG20. A Adagio adquiriu a capacidade de fabricação para a produção do ADG20 com fabricantes terceirizados para apoiar a conclusão de ensaios clínicos e lançamento comercial inicial, garantindo o potencial para o amplo acesso para as pessoas em todo o mundo, se autorizado ou aprovado para uso. Para mais informação, visite www.adagiotx.com.

Declarações de Previsão
Este comunicado para a imprensa contém declarações consideradas declarações de previsão de acordo com o Private Securities Litigation Reform Act of 1995. Palavras como “antecipa”, “acredita”, “espera”, “pretende”, “projeta”, e “futura”, e expressões similares são usadas para identificar declarações de previsão. As declarações de previsão incluem declarações sobre, entre outras coisas, a ocasião, progresso e resultados dos nossos estudos pré-clínicos e ensaios clínicos do ADG20, incluindo o início, modificação e conclusão dos estudos ou ensaios e trabalhos preparatórios relacionados, incluindo nossos planos para avaliar regimes de dosagem e outras atualizações de protocolos nos nossos ensaios clínicos, o período durante o qual os resultados dos nossos ensaios clínicos e outros estudos e atividades de pesquisa ficarão disponíveis, e nossos programas de pesquisa e desenvolvimento; nossa capacidade de obter e manter aprovações regulatórias para nossos candidatos a produtos; nossa busca de outras estratégias para abordar a variante Omicron, incluindo modificação de protocolos de ensaios clínicos; e outras declarações que não sejam de fatos históricos. Podemos não atingir os planos, intenções ou expectativas mencionadas nas nossas declarações de previsão, e você não deve depositar confiança indevida nas nossas declarações de previsão. Essas declarações de previsão envolvem riscos e incertezas que podem fazer com que nossos resultados reais sejam substancialmente diferentes dos resultados descritos ou implícitos nas declarações de previsão, incluindo, sem limitação, os impactos da pandemia de COVID-19 nos nossos negócios, ensaios clínicos e posição financeira, dados inesperados de segurança ou eficácia observados durante estudos pré-clínicos ou ensaios clínicos, a previsibilidade do sucesso clínico do ADG20 com base na atividade de neutralização nos estudos pré-clínicos, variação dos resultados nos modelos usados na previsão de atividade contra as variantes preocupantes do SARS-CoV-2, taxas de ativação ou inscrição no local de ensaios clínicos inferiores ao esperado, mudanças na concorrência esperada ou existente, mudanças no ambiente regulatório e as incertezas e o momento do processo de aprovação regulatória, incluindo os resultados das discussões sobre os ensaios clínicos Fase 2/3 com as autoridades regulatórias. Outros fatores que podem fazer com que nossos resultados reais sejam substancialmente diferentes dos resultados descritos ou implícitos nas declarações de previsão neste comunicado para a imprensa, descritos no título “Fatores de Risco” no prospecto da Adagio arquivado na Comissão de Valores Mobiliários (“SEC”) no Formulário 10-Q do trimestre encerrado em 30 de setembro de 2021, e nos relatórios futuros da Adagio a serem arquivados no SEC. Tais riscos podem ser amplificados pelos impactos da pandemia de COVID-19.  As declarações de previsão contidas neste comunicado para a imprensa são válidas a partir desta data, e a Adagio não se compromete a atualizar essas informações, exceto se exigido por lei.

Contatos:
Contato com a Mídia:
Dan Budwick, 1AB
Dan@1abmedia.com

Contato com o Investidor:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

Posted on

Adagio Therapeutics résume l’activité neutralisante de l’ADG20 contre les variants du SARS-CoV-2 et décrit ses initiatives visant à contrer Omicron

Des publications récentes de plusieurs laboratoires indépendants montrent que l’ADG20 a une activité neutralisante présentant une puissance comparable à d’autres anticorps et qui reste active contre Omicron

Plusieurs initiatives sont en cours pour traiter Omicron et les futurs variants potentiels du SARS-CoV-2

WALTHAM, Massachusetts, 14 janv. 2022 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq : ADGI), une société biopharmaceutique au stade clinique axée sur la découverte, le développement et la commercialisation de solutions à base d’anticorps pour les maladies infectieuses présentant un potentiel pandémique, a résumé aujourd’hui les conclusions récentes présentées dans trois publications distinctes qui montrent que l’ADG20, son anticorps monoclonal principal, possède une activité de neutralisation contre le variant Omicron (B.1.1.529) du SARS-CoV-2, et a présenté des initiatives visant à traiter les variants préoccupants actuels et futurs du SARS-CoV-2. Adagio évalue l’ADG20 dans le cadre de ses essais cliniques mondiaux de phase 2/3 à la fois pour la prévention et le traitement de la COVID-19. Adagio s’engage auprès de la Food and Drug Administration (FDA) des États-Unis concernant des mises à jour potentielles du protocole pour ses essais cliniques mondiaux de phase 2/3, comprenant une dose plus élevée d’ADG20 pour la prévention et le traitement potentiels de la COVID-19 résultant du variant Omicron.

L’activité neutralisante de l’ADG20 contre Omicron
Des études in vitro récemment publiées ont examiné l’activité de neutralisation de grands ensembles d’anticorps monoclonaux contre le variant Omicron sur des souches authentiques et des pseudovirus. Les résultats des trois études montrent que, parmi les anticorps monoclonaux aux derniers stades du développement clinique ou dans le cadre d’une demande d’autorisation d’utilisation d’urgence (EUA), l’ADG20 est l’un des seuls à avoir démontré une activité neutralisante contre Omicron. Les données de deux essais de neutralisation authentiques et distincts contre Omicron montrent que l’ADG20 disposait d’une concentration inhibitrice médiane, une mesure de l’activité de neutralisation, d’environ 0,4 à 1,1 µg/mL, ce qui est comparable aux deux autres anticorps monoclonaux actifs, sotrovimab et AZD7742.

« Ce qui est essentiel pour évaluer l’efficacité clinique potentielle des anticorps monoclonaux contre le SARS-CoV-2 est l’activité de neutralisation de l’anticorps monoclonal contre un variant spécifique. Bien que les résultats puissent montrer que l’ADG20 a une activité réduite contre Omicron par rapport à sa forte activité contre tous les autres variants préoccupants, y compris Delta, les données confirment que l’ADG20 fait partie des rares anticorps monoclonaux à démontrer une activité neutralisante contre le variant Omicron et justifient la poursuite de son développement », a déclaré Laura Walker, Ph.D., directrice scientifique et cofondatrice d’Adagio.

Ces résultats étayent les données in vitro précédemment communiquées d’une variété d’études précliniques qui ont montré que l’ADG20 conserve son activité contre d’autres variants préoccupants, notamment Alpha, Beta, Delta et Gamma, et que l’ADG20 conserve une activité neutralisante contre un ensemble diversifié de variants en circulation du SARS-CoV-2, y compris les variants Lambda, Mu et Delta plus.

Mise à jour de l’essai clinique portant sur Omicron
Adagio poursuit l’évaluation de l’ADG20 dans ses essais cliniques EVADE et STAMP. Adagio s’engage auprès de la FDA sur la stratégie de dosage, y compris une dose accrue d’ADG20 et d’autres mises à jour du protocole à la lumière de la propagation du variant Omicron. Adagio suspend le recrutement de nouveaux patients dans le groupe recevant une dose de 300 mg dans les deux essais cliniques alors que la société met à jour ses protocoles. Le suivi et la surveillance des patients ayant précédemment reçu l’ADG20 se poursuivent conformément aux protocoles d’origine.

Des efforts supplémentaires pour traiter Omicron et les variants futurs
En plus de la mise à jour de ses essais cliniques, Adagio poursuit plusieurs stratégies pour traiter à la fois Omicron et les variants futurs qui pourraient potentiellement émerger. Tirant parti de son partenariat exclusif avec Adimab LLC, un leader mondial de l’ingénierie des anticorps, Adagio explore la possibilité de modifier l’ADG20 pour améliorer davantage la liaison avec le variant Omicron afin d’améliorer son activité de neutralisation contre Omicron tout en conservant sa large neutralisation contre les autres variants préoccupants du SARS-CoV-2. Parallèlement, Adagio évalue l’activité de neutralisation contre Omicron de plusieurs centaines d’anticorps monoclonaux issus de sa bibliothèque exclusive d’anticorps SARS-CoV-2 précédemment isolés. Ces anticorps monoclonaux neutralisants supplémentaires pourraient être développés en tant que produit autonome ou dans le cadre d’une approche combinée. Ces efforts sont en cours et la société prévoit de publier les conclusions préliminaires de ses recherches au cours du premier trimestre 2022.

« Le SARS-CoV-2 est un virus qui évolue rapidement, et chez Adagio, nous sommes déterminés à nous adapter le plus vite possible. Il apparaît très clairement qu’aucun produit unique ne répondra pleinement à la nature en constante évolution de la pandémie de COVID-19, et que plusieurs solutions préventives et thérapeutiques sont nécessaires. Sur la base des données internes et des conclusions de tiers, nous sommes convaincus que l’ADG20 peut être un outil important dans la lutte contre ce virus », a ajouté Tillman Gerngross, Ph.D., co-fondateur et président-directeur général d’Adagio.

À propos de l’ADG20
L’ADG20, un anticorps monoclonal expérimental ciblant la protéine spike du SARS-CoV-2 et des coronavirus connexes, est évalué par le biais d’essais cliniques mondiaux aux fins de la prévention et du traitement de la COVID-19, la maladie provoquée par le SARS-CoV-2. L’ADG20 a été conçu en vue d’offrir de puissantes et vastes capacités de neutralisation du SARS-CoV-2 et des autres sarbecovirus du clade 1 permettant de cibler un épitope bien conservé dans le domaine de fixation du récepteur. L’ADG20 a également été conçu pour fournir une demi-vie prolongée pour une protection durable. Les données in vitro issues d’une variété d’études précliniques ont montré que l’ADG20 conserve une activité neutralisante contre tous les variants préoccupants connus du SARS-CoV-2. Dans un essai de phase 1, l’ADG20 a été bien toléré sans signaux d’innocuité identifiés au cours d’un suivi d’au moins trois mois dans toutes les cohortes. L’utilisation de l’ADG20 n’a été approuvée dans aucun pays, par ailleurs, l’innocuité et l’efficacité n’ont pas encore été établies.

À propos d’Adagio Therapeutics
Adagio (Nasdaq : ADGI) est une société biopharmaceutique au stade clinique axée sur la découverte, le développement et la commercialisation de solutions à base d’anticorps pour les maladies infectieuses présentant un potentiel pandémique, y compris la COVID-19 et la grippe. Le portefeuille d’anticorps de la société a été optimisé grâce aux capacités de pointe d’Adimab en matière d’ingénierie d’anticorps et est conçu pour fournir aux patients et aux cliniciens une combinaison potentielle inégalée de puissance, d’ampleur, de protection durable (grâce à l’extension de la demi-vie), de faisabilité de fabrication et de prix abordable. Le portefeuille d’anticorps contre le SARS-CoV-2 d’Adagio comprend plusieurs anticorps fortement neutralisants non concurrents dotés d’épitopes de liaison distincts, dirigés par l’ADG20. Adagio a conclu avec des sous-traitants tiers un contrat portant sur des capacités de fabrication pour la production de l’ADG20 afin de soutenir l’achèvement des essais cliniques et le lancement commercial initial, garantissant ainsi une large accessibilité potentielle aux populations du monde entier, si son utilisation est autorisée ou approuvée. Pour plus d’informations, rendez-vous sur notre site www.adagiotx.com.

Énoncés prospectifs
Le présent communiqué de presse contient des énoncés prospectifs au sens de la loi Private Securities Litigation Reform (Réforme sur la résolution des litiges portant sur des titres privés) de 1995. Des mots tels que « anticipe », « croit », « s’attend à », « a l’intention de », « prévoit » et « à l’avenir » ou des expressions similaires sont destinés à identifier des énoncés prospectifs. Les énoncés prospectifs comprennent des énoncés concernant, entre autres, le calendrier, les progrès et les résultats de nos études précliniques et essais cliniques sur l’ADG20, y compris le lancement, la modification et l’achèvement d’études ou d’essais et de travaux préparatoires connexes, y compris nos plans visant à évaluer la posologie et d’autres mises à jour de nos essais cliniques, la période durant laquelle les résultats de nos essais cliniques et autres études et activités de recherche seront disponibles ainsi que nos programmes de recherche et développement ; notre capacité à obtenir et conserver des approbations réglementaires pour nos produits candidats ; notre mise en œuvre d’autres stratégies pour contrer le variant Omicron, y compris la modification de nos protocoles d’essais cliniques ; et les autres déclarations qui ne sont pas des faits historiques. Nous pourrions ne pas réellement réaliser les plans, intentions ou attentes divulgués dans nos énoncés prospectifs et vous ne devez pas vous fier indûment à nos énoncés prospectifs. Ces énoncés prospectifs impliquent des risques et des incertitudes qui pourraient amener nos résultats réels à différer sensiblement des résultats décrits ou sous-entendus par les énoncés prospectifs, y compris, sans limitation, les impacts de la pandémie de COVID-19 sur nos activités, nos essais cliniques et notre situation financière, les données d’innocuité ou d’efficacité inattendues observées lors d’études précliniques ou d’essais cliniques, le caractère prévisible du succès clinique de l’ADG20 sur la base de l’activité neutralisante dans des essais précliniques, la variabilité des résultats dans les modèles utilisés pour prévoir l’activité contre les variants préoccupants du SARS-CoV-2, les taux d’activation ou de recrutement de sites d’essai clinique qui sont inférieurs aux prévisions, l’évolution de la concurrence attendue ou existante, les changements dans l’environnement réglementaire, et les incertitudes et le calendrier du processus d’approbation réglementaire, y compris les résultats de nos discussions avec les autorités règlementaires concernant nos essais cliniques de phase 2/3. D’autres facteurs pouvant causer une différence matérielle entre nos résultats réels et ceux exprimés ou sous-entendus dans les énoncés prospectifs de ce communiqué de presse sont décrits sous la rubrique « Risk Factors » (Facteurs de risque) du rapport trimestriel d’Adagio sur le formulaire 10-Q pour le trimestre clos le 30 septembre 2021 et dans les futurs rapports qu’Adagio déposera auprès de la SEC. De tels risques peuvent être amplifiés par les impacts de la pandémie de COVID-19.  Les énoncés prospectifs contenus dans le présent communiqué de presse sont formulés à cette date, et Adagio décline toute obligation de mettre à jour ces informations sauf si la loi en vigueur l’exige.

Contacts :
Contact auprès des médias :
Dan Budwick, 1AB
Dan@1abmedia.com

Contact auprès des investisseurs :
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

Posted on

Date limite de participation finale prolongée lors des Prix Stevie® 2022 pour les ventes et le service à la clientèle

Les participants peuvent soumettre leurs candidatures jusqu’au 2 février aux prix des meilleures ventes et du service à la clientèle

FAIRFAX, Virginie, 13 janv. 2022 (GLOBE NEWSWIRE) — À la demande générale, les Prix Stevie® ont prolongé la date limite de participation finale de la 16e édition annuelle des Prix Stevie® pour les ventes et le service à la clientèle au mercredi 2 février. La date limite de participation initiale était le 12 janvier. Il s’agit des plus grands prix au monde pour les professionnels, les équipes et les organisations de la vente et du service à la clientèle.

Les dossiers de participation et les détails complets sur le concours sont disponibles à l’adresse http://www.StevieAwards.com/Sales.

Les candidats éligibles incluent les départements, les équipes et les professionnels du monde entier qui travaillent dans le service à la clientèle, les centres de contact, le développement commercial et les ventes. Les nouveaux produits, services et fournisseurs de solutions utilisés par ces professionnels sont également éligibles. Les prix 2022 récompenseront les réalisations depuis le 1er juillet 2019.

Les gagnants seront annoncés le 28 février 2022. Les lauréats des Prix Stevie d’or, d’argent et de bronze seront célébrés lors d’une cérémonie virtuelle de remise des prix le 11 mai.

Les Prix Stevie pour les ventes et le service à la clientèle présentent plus de 150 prix dans les catégories ventes, service à la clientèle, développement commercial, nouveaux produits et fournisseurs de solutions. Les participants peuvent soumettre autant de nominations qu’ils le souhaitent dans toutes les catégories.

Nouveauté cette année, pour toutes les catégories, les exigences en matière de présentation ont été étendues pour permettre aux nominations d’inclure les réalisations des deux dernières années au lieu d’une seule.

Il existe de nombreuses nouvelles catégories pour 2022, notamment Ingénieur commercial de l’année, Professionnel du support commercial de l’année, Professionnel virtuel et pré-vente de l’année, Innovation de vente à distance de l’année et Employeur commercial de l’année, ainsi qu’une toute nouvelle section de catégories récompensant les réalisations de Leadership éclairé dans les domaines du développement commercial, du service à la clientèle et des ventes.  Découvrez toutes les catégories ici.

Les Prix Stevie ont également le plaisir de présenter le Prix de l’éthique dans les ventes, sponsorisé par Sales Partnerships. Cette catégorie n’a aucun frais de participation. Ce prix récompense les organisations pour leurs meilleures pratiques et leurs réalisations dans la démonstration des normes éthiques les plus élevées du secteur des ventes. Les participants peuvent soumettre des exemples spécifiques, des études de cas, des pratiques, etc. qui illustrent pourquoi l’organisation nominée doit être considérée comme un excellent exemple des meilleures pratiques de vente. Ce prix est basé sur les activités menées en 2021.

Maggie Miller, présidente des Prix Stevie, a commenté : « Chaque année, nos juges sont de plus en plus impressionnés par les candidatures soumises aux Prix Stevie pour les ventes et le service à la clientèle. Nous encourageons toute organisation qui souhaite être reconnue pour ses réalisations depuis juillet 2019 à demander un dossier d’inscription afin de voir quelles catégories souligneraient le mieux ces réussites. »

Les lauréats de l’édition 2021 des Prix Stevie pour les ventes et le service à la clientèle comprenaient la Croix-Rouge américaine, Blackbaud, Inc., Carbonite, Cisco Systems Inc., ClassicCars.com, DHL Express, ElectronicArts, GoDaddy, IBM, John Hancock Financial Solutions, Land O’Lakes, Mailchimp, Modern Campus, Nasdaq Governance Solutions, Nutrisystem, Paylocity, SoftPro, Travelzoo, ValueSelling Associates, VIZIO, Inc., Vodafone Turkey et bien plus encore.

Le concours 2022 sera jugé par plus de 150 professionnels à travers le monde.

À propos des Prix Stevie
Les Prix Stevie sont décernés dans huit programmes : les Prix Stevie en Asie-Pacifique, les Prix Stevie en Allemagne, les American Business Awards®, les International Business Awards®, les Prix Stevie pour les grands employeurs, les Prix Stevie pour les femmes entrepreneurs, les Prix Stevie pour les ventes et le service à la clientèle et les Prix Stevie pour le Moyen-Orient et l’Afrique du Nord. Les concours des Prix Stevie reçoivent chaque année plus de 12 000 nominations émanant d’entreprises de plus de 70 pays. En récompensant les entreprises de tous types et de toutes tailles, ainsi que leurs collaborateurs, les Prix Stevie reconnaissent les performances exceptionnelles sur le lieu de travail dans le monde entier. Pour en savoir plus sur les Prix Stevie, rendez-vous sur le site http://www.StevieAwards.com.

Contact marketing :
Nina Moore
+1 (703) 547-8389
Nina@StevieAwards.com

Une photo accompagnant cette annonce est disponible à l’adresse https://www.globenewswire.com/NewsRoom/AttachmentNg/ad785517-4799-4518-88e5-b3b0127ed355

Posted on

Prazo de Inscrição Final Estendido para os Stevie® Awards de 2022 de Vendas e Atendimento ao Cliente

Os participantes podem enviar indicações para os principais prêmios de vendas e atendimento ao cliente até 2 de fevereiro

FAIRFAX, Va., Jan. 13, 2022 (GLOBE NEWSWIRE) — Por demanda popular, o prazo final para inscrições no 16o Anual Stevie® Awards de Vendas e Atendimento ao Cliente foi prorrogado para quarta-feira, dia 2 de fevereiro. O prazo final original para inscrição era 12 de janeiro. Estes são os principais prêmios do mundo para profissionais equipes e organizações de vendas e atendimento ao cliente.

Os kits de inscrição e os detalhes completos do concurso podem ser obtidos em http://www.StevieAwards.com/Sales.

Os indicados elegíveis incluem departamentos, equipes e profissionais de todo o mundo que trabalhem em atendimento ao cliente, central de atendimento, desenvolvimento de negócios e vendas. Provedores de novos produtos, serviços e de soluções usados por esses profissionais também são elegíveis. Os prêmios de 2022 reconhecerão as conquistas a partir de 1º de julho de 2019.

Os nomes dos vencedores serão divulgados no dia 28 de fevereiro de 2022. Os vencedores do Stevie Award Ouro, Prata e Bronze serão homenageados em uma cerimônia de premiação virtual no dia 11 de maio.

O Stevie Awards de Vendas e Atendimento ao Cliente abrangem mais de 150 categorias de prêmios de vendas, prêmios de atendimento ao cliente, prêmios de desenvolvimento de negócios, prêmios de novos produtos, e de prêmios de provedores de solução. Os participantes podem enviar um número ilimitado de nomeações a quantas categorias quiserem.

Novo este ano, para todas as categorias, os requisitos para envio foram ampliados para permitir que as nomeações incluam realizações nos últimos dois anos em vez de um ano.

Existem muitas novas categorias para 2022, incluindo Engenheiro de Vendas do Ano, Profissional de Suporte de Vendas do Ano, Profissional Virtual e de Pré-Vendas do Ano, Inovação de Vendas Remotas do Ano, Empregador de Vendas do Ano e uma seção inteiramente nova de categorias para reconhecer as conquistas da Liderança de Pensamento no desenvolvimento de negócios, atendimento ao cliente e vendas.  Explore todas as categorias aqui.

Os Stevie Awards também têm o prazer de apresentar o Prêmio Ética em Vendas, patrocinado pela Sales Partnerships. Esta categoria não tem taxa de inscrição. Este prêmio reconhece as organizações por suas melhores práticas e realizações, demonstrando os mais altos padrões éticos no setor de vendas. Os participantes podem enviar exemplos específicos, estudos de caso, práticas, etc. que mostrem o motivo pelo qual a organização que está sendo nomeada deve ser considerada um excelente exemplo de melhores práticas em vendas. Este prêmio tem por base as atividades de 2021.

A presidente dos Stevie Awards, Maggie Miller, disse: “Todos os anos os nossos juízes ficam cada vez mais impressionados com as inscrições nos Stevie Awards de Vendas e Atendimento ao Cliente. Qualquer organização que queira ser reconhecida por suas conquistas a partir de julho de 2019 deve solicitar um kit de inscrição para saber quais categorias melhor destacariam esses sucessos.”

Os vencedores da edição de 2021 dos Stevie Awards de Vendas e Serviço ao Cliente incluíram American Red Cross, Blackbaud, Inc., Carbonite, Cisco Systems Inc., ClassicCars.com, DHL Express, ElectronicArts, GoDaddy, IBM, John Hancock Financial Solutions, Land O’Lakes, Mailchimp, Modern Campus, Nasdaq Governance Solutions, Nutrisystem, Paylocity, SoftPro, Travelzoo, ValueSelling Associates, VIZIO, Inc., Vodafone Turkey e muitos outros.

O concurso de 2022 será julgado por mais de 150 profissionais de todo o mundo.

Sobre os Stevie Awards
Os Stevie Awards são concedidos em oito programas: Stevie Awards Ásia-Pacífico, Stevie Awards Alemão, The American Business Awards®, The International Business Awards®, Stevie Awards para Grandes Empregadoras, Stevie Awards para Mulheres Empresariais, Stevie Awards de Vendas e Serviço ao Cliente e o Stevie Awards para o Oriente Médio e África do Norte. Os concursos Stevie Awards recebem mais de 12.000 nomeações todos os anos de empresas de mais de 70 países. Honrando empresas de todos os tipos e tamanhos, e as pessoas por trás delas, os Stevies reconhecem excelente desempenho no local de trabalho em todo o mundo. Saiba mais sobre os Stevie Awards em http://www.StevieAwards.com.

Contato de Marketing:
Nina Moore
Nina@StevieAwards.com
+1 (703) 547-8389

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/ad785517-4799-4518-88e5-b3b0127ed355